Investors & Media
Featured News: CSL and uniQure Win 2023 Prix Galien USA Award
At uniQure, the dual potential for life-changing gene therapies and long-term investor returns creates a unique—and uniquely exciting—opportunity.
Press Releases
Subscribe to receive breaking news alerts about uniQure.
Subscribe-
-
uniQure Provides Regulatory Update on AMT-130 for Huntington’s Disease
-
uniQure to Announce 2025 Financial Results
Stock Information
Updated stock ticker information for uniQure
- NASDAQ:
- Price:
- Change:
- Volume:
(Updated every 15 minutes)
SEC Filings
Security and exchange commission filings for uniQure, including quarterly and annual reports
Learn MoreUpcoming Webcasts
No webcasts scheduled. Check back soon.
Webcast Archive
-
uniQure Fourth Quarter and Year End 2025 Earnings Call
8:00 a.m. ET - 9:00 a.m. ET
View Webcast -
TD Cowen 46th Annual Health Care Conference
10:30 a.m. ET - 11:00 a.m. ET
View Webcast -
uniQure Third Quarter 2025 Earnings Call
8:30 a.m. ET - 9:30 a.m. ET
View Webcast
Investor Presentations
-
Corporate Presentation – January 2026
View Presentation -
Pivotal Phase I/II AMT-130 Huntington's Disease - September 2025 – Webcast Presentation
View Presentation -
CHDI - 2026 HD Therapeutics Conference – AMT-130: Propensity Score Adjustment Mitigates Potential Bias from Striatal Volume Absence in Enroll-HD
View Presentation -
2026 WORLDSympsium – AMT-191 investigational gene therapy in adult males with classic Fabry disease; preliminary safety and biomarker data of Phase I/IIa study
View Presentation -
Epilepsy Therapeutics & Diagnostics Development Symposium (ETDD) – GenTLE clinical study of AMT-260
View Presentation